An international study involving DPU investigates how MRI can support treatment response assessment and prognostic evaluation in recurrent medulloblastoma.
© Pixabay
MRI for Assessing Treatment Response
Published in the European Journal of Radiology, the study “Assessment of treatment response in recurrent medulloblastoma using craniospinal MRI” examines the use of craniospinal magnetic resonance imaging (MRI) to assess treatment response in recurrent medulloblastoma.
Univ.-Prof. PD Dr. Julia Furtner-Srajer, PhD, MBA, from Danube Private University (DPU) contributed to the international research. The study was based on MRI scans from 40 patients with recurrent medulloblastoma who received anti-angiogenic therapy as part of the MEMMAT study.
Tumour Volume as a Potential Prognostic Indicator
The findings show that in patients who responded well to therapy, both the number and volume of tumour lesions decreased. In cases of disease progression, both parameters increased.
Furthermore, a higher tumour volume before treatment initiation was associated with significantly shorter overall survival. Combining different MRI sequences and jointly analysing imaging data from the brain and spinal cord may provide additional information for assessing disease progression.
The findings highlight the potential of quantitative MRI analyses to provide a more differentiated assessment of treatment response and support prognostic evaluation in recurrent medulloblastoma.
Read the publication in the European Journal of Radiology:
https://doi.org/10.1016/j.ejrad.2026.113056
